Secondary stroke prevention in the elderly: new evidence in hypertension and hyperlipidemia.

Recurrent stroke is a major public health concern, occurring in approximately one third of stroke survivors within 5 years. Besides, the overall aging of the developed countries population and the improved survival of patients with stroke have created a large population of older adults in need of secondary stroke prevention. Thus, at present, more than 5% of individuals 65 to 74 years old and more than 10% of those 75 and older have had a prior stroke. An age bias exists in the prescription of important secondary-preventive therapies in the elderly. Knowledge of the evidence behind the secondary prevention strategies could be useful to practicing physicians caring for stroke elderly patients. Effective strategies for the secondary prevention of stroke include treatment of hypertension and hyperlipidaemia. Our review presents the most recent evidence on hypertension and lipid lowering therapy for stroke prevention in elderly patients with previous stroke or TIA. Basis for evidence (or the lack thereof), areas of controversy, and avenues of future focus for these treatments are also discussed in this paper.

[1]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[2]  E. O’Brien,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.

[3]  A. Rigaud,et al.  Hypertension in older adults. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  Karla Kerlikowske,et al.  Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials , 1999, The Lancet.

[5]  Jennifer G. Robinson,et al.  Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly? , 2007, Stroke.

[6]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[7]  R. D'Agostino,et al.  Secular Trends in Stroke Incidence and Mortality: The Framingham Study , 1992, Stroke.

[8]  C. Anderson,et al.  Trends in Incidence and Outcome of Stroke in Perth, Western Australia During 1989 to 2001: The Perth Community Stroke Study , 2008, Stroke.

[9]  P. Macfarlane,et al.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.

[10]  J. Staessen,et al.  The Systolic Hypertension in Europe Trial , 2000 .

[11]  J. Staessen,et al.  Blood Pressure Lowering for Primary and Secondary Prevention of Stroke , 2006, Hypertension.

[12]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[13]  M. Hennerici,et al.  Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack , 2009, Neurology.

[14]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[15]  Russell Steele,et al.  Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. , 2008, Journal of the American College of Cardiology.

[16]  Barry J. Davis,et al.  Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial , 1998, Annals of Internal Medicine.

[17]  H. Krumholz,et al.  Systolic hypertension in older persons , 2004 .

[18]  P. Touboul,et al.  Up-to-Date Meta-Analysis Statins in Stroke Prevention and Carotid Atherosclerosis : Systematic Review and , 2004 .

[19]  A. Dominiczak,et al.  2007 ESH‐ESC Guidelines for the management of arterial hypertension , 2007 .

[20]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[21]  S. Sidney,et al.  Short-term prognosis after emergency department diagnosis of TIA. , 2000, JAMA.

[22]  A. Algra,et al.  Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study , 2005, The Lancet.

[23]  A. Kalache,et al.  Active ageing: a policy framework. , 2003, Advances in gerontology = Uspekhi gerontologii.

[24]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[25]  K. Alexander,et al.  Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. , 2007, The American journal of geriatric pharmacotherapy.

[26]  H. Krumholz,et al.  Systolic hypertension in older persons. , 2004, JAMA.

[27]  W. Elliott.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials , 2009 .

[28]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[29]  B. Psaty,et al.  Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly , 2005, Neurology.

[30]  Sc Prospective,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .

[31]  Pats-Collaborating-Group-.  Post-stroke antihypertensive treatment study. A preliminary result , 1995 .

[32]  W. Aronow.  Managing Hyperlipidaemia in the Elderly , 2006, Drugs & aging.

[33]  H. Diener,et al.  Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES) , 2005, Stroke.

[34]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[35]  W. Kirkendall.  Treatment of hypertension in the elderly. , 1986, The American journal of cardiology.

[36]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[37]  S. Lewington.  Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[38]  V. Chair,et al.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the , 2006, Circulation.

[39]  O. Faergeman,et al.  Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.

[40]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[41]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[42]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[43]  N. Wenger,et al.  Secondary prevention of coronary heart disease in elderly patients. , 2005, American family physician.

[44]  B. Stegmayr,et al.  Favorable Trends in the Incidence and Outcome in Stroke in Nondiabetic and Diabetic Subjects: Findings From the Northern Sweden MONICA Stroke Registry in 1985 to 2003 , 2008, Stroke.

[45]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[46]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[47]  M. C. F. Moreno,et al.  Statins in stroke prevention: What an internist should know , 2008 .

[48]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[49]  T. Jacobson,et al.  Initiating statins in the elderly: the evolving challenge , 2008, Current opinion in endocrinology, diabetes, and obesity.